(Q43446368)

23 November 2017

0 references

Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials (English)

1 reference

23 November 2017

1 reference

1 reference

M Monami

1

1 reference

23 November 2017

I Dicembrini

2

1 reference

23 November 2017

C Nardini

3

1 reference

23 November 2017

I Fiordelli

4

1 reference

23 November 2017

E Mannucci

5

1 reference

23 November 2017

28 July 2013

1 reference

Diabetes, Obesity and Metabolism

23 November 2017

1 reference

23 November 2017

16

1 reference

23 November 2017

1

1 reference

23 November 2017

38-47

1 reference

Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials

23 November 2017

1 reference

Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis

21 January 2018

1 reference

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

21 January 2018

1 reference

Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials

21 January 2018

1 reference

Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk

21 January 2018

1 reference

Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.

21 January 2018

1 reference

Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials

21 January 2018

1 reference

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.

21 January 2018

1 reference

Heart rate and cardiovascular mortality: the Framingham Study

21 January 2018

1 reference

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

Operating characteristics of a rank correlation test for publication bias

21 January 2018

1 reference

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis

21 January 2018

1 reference

Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials.

21 January 2018

1 reference

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

21 January 2018

1 reference

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12175

1 reference

23 November 2017

1 reference